Recro Pharma Reports Third Quarter 2016 Financial Results
Nov 10, 2016 12:01 pm UTC| Business
Announced Positive Phase III Results from Pivotal Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam Following Mini Abdominoplasty Surgery Ongoing; Top-line Data Expected by Year...
Recro Pharma Reports Third Quarter 2016 Financial Results
Nov 10, 2016 12:01 pm UTC| Business
Announced Positive Phase III Results from Pivotal Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam Following Mini Abdominoplasty Surgery Ongoing; Top-line Data Expected by Year...
VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
Nov 10, 2016 12:01 pm UTC| Business
TEL AVIV, Israel, Nov. 10, 2016 -- VBL Therapeutics (NASDAQ:VBLT), today reported financial results and provided a business update for the third quarter and nine month period ended September 30, 2016. “We continue to...
VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
Nov 10, 2016 12:01 pm UTC| Business
TEL AVIV, Israel, Nov. 10, 2016 -- VBL Therapeutics (NASDAQ:VBLT), today reported financial results and provided a business update for the third quarter and nine month period ended September 30, 2016. “We continue to...
Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank
Nov 10, 2016 12:01 pm UTC| Business
NEW YORK, Nov. 10, 2016 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today...
Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank
Nov 10, 2016 12:01 pm UTC| Business
NEW YORK, Nov. 10, 2016 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today...
Nov 10, 2016 12:01 pm UTC| Business
SAN DIEGO and TORONTO, Nov. 10, 2016 -- Aptose Biosciences Inc. (Aptose) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of...